E
Salarius Pharmaceuticals, Inc. SLRX
$0.7299 -$0.0029-0.40% NASDAQ
Recommendation
Prev Close
$0.73275
Volume
11,640
Avg Vol (90D)
1,610,335
Market Cap
$1.28M
Dividend & Yield
--
52-Week Range
$0.4519 - $7.20
P/E (TTM)
--
EPS (TTM)
-$7.42
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update
4/16/2025 - Ticker Report
Salarius Pharmaceuticals announces Langer to join SAB
4/16/2025 - The Fly
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor ...
4/16/2025 - GuruFocus
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
4/16/2025 - Globe Newswire
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors ...
3/26/2025 - GuruFocus
Salarius Pharmaceuticals merger partner announces series of drug candidates
3/26/2025 - The Fly
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
3/26/2025 - Globe Newswire
Salarius Pharmaceuticals GAAP EPS of -$5.79
3/24/2025 - SeekingAlpha.com: All News
Salarius Pharmaceuticals sees cash runway through later part of 2Q25
3/24/2025 - The Fly
Salarius Pharmaceuticals reports FY24 EPS ($5.79) vs. ($30.74) last year
3/24/2025 - The Fly
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
3/24/2025 - GuruFocus
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
3/24/2025 - Globe Newswire
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase ...
2/3/2025 - GuruFocus
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
2/3/2025 - Globe Newswire
Salarius Pharmaceuticals files to sell common stock, warrants, no amount given
1/21/2025 - TipRanks Financial Blog
Salarius Pharmaceuticals files to sell common stock, warrants, no amount given
1/21/2025 - The Fly
$HAREHOLDER ALERT: The MandA Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. SLRX
1/14/2025 - Globe Newswire
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. ...
1/14/2025 - GuruFocus
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
1/13/2025 - Business Wire
Houston's Salarius Pharmaceuticals to merge with Gates Foundation-backed co., focus on Covid-19 treatment
1/13/2025 - Bizjournals.com - Health Care News
Salarius Pharmaceuticals and Decoy Therapeutics announce merger
1/13/2025 - Seeking Alpha - Healthcare
Salarius Pharmaceuticals and Decoy Therapeutics announce merger
1/13/2025 - SeekingAlpha.com: All News
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement
1/13/2025 - GuruFocus
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement
1/13/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$5.73M
EBIT (TTM)
-$5.73M
Net Income (TTM)
-$5.58M
Balance Sheet
Total Assets (Q)
$3.02M
Total Debt (Q)
$221.90K
Total Liabilities (Q)
$1.51M
Book Value Per Share (Q)
$1.05
Cash Flow
Cash from Operations (TTM)
-$4.53M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$1.06M
Net Change in Cash (TTM)
-$3.47M
Filings
Filing Date
Friday, March 21, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.13
7-Day Total Return
8.66%
30-Day Total Return
-24.75%
60-Day Total Return
-66.05%
90-Day Total Return
-50.34%
Year to Date Total Return
-58.05%
1-Year Total Return
-81.57%
2-Year Total Return
-94.40%
3-Year Total Return
-98.66%
5-Year Total Return
-99.57%
52-week Low
Apr 09, 2025 - $0.4519
52-week High
Jul 23, 2024 - $7.20
Valuation
Market Cap
$1.28M - Nano Cap
Enterprise Value
-$933.48K
Price/Sales (TTM)
--
Price/Book (Q)
0.70
Dividends and Shares
Shares Outstanding
1.44M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.salariuspharma.com
Phone Number
(713) 913-5608
Address
2450 Holcombe Blvd.
Houston, TX 77021
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat... more
NASDAQ 04/28/2025 10:17AM Eastern Quotes delayed